BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to TrialGlobeNewsWire • 07/26/22
BridgeBio Pharma and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type APRNewsWire • 07/25/22
BridgeBio Pharma Announces Academic Collaboration with Baylor College of Medicine to Advance Potential Therapies to Treat Genetic DiseasesGlobeNewsWire • 07/21/22
BridgeBio Pharma Announces Founding Affiliation with Bakar Labs, Incubator at UC Berkeley's Bakar BioEnginuity HubGlobeNewsWire • 07/21/22
BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone FormersGlobeNewsWire • 06/27/22
BridgeBio Pharma Posts Promising Data From Gene Therapy Trial In Ultra-Rare DiseaseBenzinga • 06/22/22
BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan DiseaseGlobeNewsWire • 06/22/22
BridgeBio Pharma Shares Positive Phase 2b Data and Announces Pivotal Study Design for Phase 3 Trial of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1)GlobeNewsWire • 06/13/22
BridgeBio Pharma Affiliate Venthera Presents Preliminary Results from Clinical Trial of VT30 (BBP-681) for Venous, Lymphatic, and Venolymphatic MalformationsGlobeNewsWire • 06/10/22
BridgeBio Pharma to Present Phase 2b Data and Pivotal Phase 3 Study Design of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual ConferenceGlobeNewsWire • 06/09/22
BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic AcidemiasGlobeNewsWire • 05/26/22
BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)GlobeNewsWire • 05/20/22
BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment on Senior Debt by Two YearsGlobeNewsWire • 05/13/22
BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in OncologyGlobeNewsWire • 05/12/22
BridgeBio Pharma to Participate in the Bank of America Securities Healthcare ConferenceGlobeNewsWire • 05/10/22
BridgeBio Shares Plunge After it Details Out-Licensing Plans For 'Restructuring Initiative'Benzinga • 05/05/22
BridgeBio Pharma (BBIO) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/05/22
BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business UpdateGlobeNewsWire • 05/05/22
BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)GlobeNewsWire • 04/03/22
BridgeBio Pharma to Present Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American College of Cardiology (ACC) Annual Scientific Session & ExpoGlobeNewsWire • 03/28/22
BridgeBio: Potential Based On Diverse Pipeline Targeting KRAS Mutations And Rare DiseasesSeeking Alpha • 03/22/22
